Last 699.00 GBp
Change Today +24.50 / 3.63%
Volume 603.5K
BTG On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 10:43 AM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

btg plc (BTG) Snapshot

Open
675.50 GBp
Previous Close
674.50 GBp
Day High
699.00 GBp
Day Low
674.50 GBp
52 Week High
09/30/14 - 699.00 GBp
52 Week Low
10/9/13 - 365.30 GBp
Market Cap
2.5B
Average Volume 10 Days
614.5K
EPS TTM
0.07 GBp
Shares Outstanding
362.6M
EX-Date
06/7/00
P/E TM
100.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for BTG PLC (BTG)

Related News

No related news articles were found.

btg plc (BTG) Related Businessweek News

No Related Businessweek News Found

btg plc (BTG) Details

BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

860 Employees
Last Reported Date: 06/16/14
Founded in 1948

btg plc (BTG) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.0M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 657.0K GBP
Compensation as of Fiscal Year 2014.

btg plc (BTG) Key Developments

BTG plc Announces Executive Changes

BTG plc announced that Melanie Lee, PhD, CBE, FMedSci, DSc (Hons), has been appointed as part time Chief Scientific Officer to BTG, effective from 1 November 2014. As a consequence, Melanie has retired from the Board of Directors of BTG, which she joined as a non-executive director on 29 November 2010.

BTG plc - Analyst/Investor Day

BTG plc - Analyst/Investor Day

BTG plc Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014

BTG plc Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 . Venue: The Grand Hyatt Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTG:LN 699.00 GBp +24.50

BTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hikma Pharmaceuticals PLC 1,723 GBp +98.00
Merit Medical Systems Inc $11.96 USD -0.036
Pfizer Ltd/India 1,663 INR +25.20
RPX Corp $14.13 USD -0.23
Wi-Lan Inc C$4.02 CAD -0.03
View Industry Companies
 

Industry Analysis

BTG

Industry Average

Valuation BTG Industry Range
Price/Earnings 97.3x
Price/Sales 8.2x
Price/Book 4.5x
Price/Cash Flow 50.1x
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.